Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. The company's lead program is xB3-001, an xB3 peptide vector-trastuzumab fusion. It is developing xB3, a proprietary platform technology for the delivery of therapeutics and imaging agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders in the areas of high unmet medical needs, including brain cancers, and metabolic and neurodegenerative diseases. The company's in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain metastases, glioblastomas, and neurodegenerative diseases. Bioasis Technologies Inc. has a collaborative research agreement with CQDM and Brain Canada to perform research on the delivery of therapeutic compounds across the BBB; and a strategic collaboration with BIOAGILYTIX for the development and validation of bioanalytical methods to support the xB3 TM-001 program, as well with WuXi Biologics (Hong Kong) Limited for the development and manufacturing of xB3-001 to treat cancer. The company was incorporated in 2006 and is headquartered in Guilford, Connecticut.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+1-604-2957014
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesC$1.76 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date2/4/2020 (Estimated)
OptionableOptionable
biOasis Technologies (CVE:BTI) Frequently Asked Questions
What is biOasis Technologies' stock symbol?
biOasis Technologies trades on the Canadian Venture Exchange (CVE) under the ticker symbol "BTI."
When is biOasis Technologies' next earnings date?
Has biOasis Technologies been receiving favorable news coverage?
News stories about BTI stock have been trending somewhat negative this week, InfoTrie Sentiment reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. biOasis Technologies earned a coverage optimism score of -1.9 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for biOasis Technologies.
Who are some of biOasis Technologies' key competitors?
Some companies that are related to biOasis Technologies include Emerald Health Therapeutics (EMH), Tiziana Life Sciences (TILS), IntelGenx Technologies (IGX), ReNeuron Group (RENE), Protalix Biotherapeutics (PLX), Asterias Biotherapeutics (AST), Zelda Therapeutics (ZLD), Covalon Technologies (COV), OptiBiotix Health (OPTI), AquaBounty Technologies (AQB), Actinium Pharmaceuticals (ATNM), Actinium Pharmaceuticals (ATNM), Nuformix (NFX), Biotron (BIT) and Bionomics (BNO).
What other stocks do shareholders of biOasis Technologies own?
Who are biOasis Technologies' key executives?
biOasis Technologies' management team includes the folowing people:
- Dr. Deborah Ann Rathjen B.Sc. (Hons.), Q.C., Ph.D., M.A.I.C.D., FTSE, Exec. Chair, CEO & Pres (Age 61)
- Ms. Christine Antalik, Chief Financial Officer (Age 48)
- Mr. Graeme Dick, Director of Investor Relations
- Mr. Kim Elton, Director of Marketing
- Mr. Doug Williams MBA, Exec. VP & Chief Bus. Officer
How do I buy shares of biOasis Technologies?
Shares of BTI and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is biOasis Technologies' stock price today?
One share of BTI stock can currently be purchased for approximately C$0.21.
How big of a company is biOasis Technologies?
What is biOasis Technologies' official website?
How can I contact biOasis Technologies?
biOasis Technologies' mailing address is 130-10691 Shellbridge Way, RICHMOND, BC V6X 2W8, Canada. The company can be reached via phone at +1-604-2957014.
MarketBeat Community Rating for biOasis Technologies (CVE BTI)
MarketBeat's community ratings are surveys of what our community members think about biOasis Technologies and other stocks. Vote "Outperform" if you believe BTI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BTI will underperform the S&P 500 over the long term. You may vote once every thirty days.
